explore -WSS

explore

author：Wikipedia 2025-08-26 23:48:40 - browse：57

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Shifting the focus from loneliness to social health

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

At ASCO, AstraZeneca reports strong data for breast cancer drug

At ASCO, AstraZeneca reports strong data for breast cancer drug

Letters to First Opinion on caregivers, digital health, and more

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Medical experts exlpore how to eliminate bias in clinical algorithms

hotspot

explore

entertainment

Psychedelics group wrestles with new pharma identity

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Activists slam private health insurers over coverage restrictions

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Supreme Court strikes down use of affirmative action

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

The cancer drug shortage isn’t new — and neither are the solutions

At ASCO, AstraZeneca reports strong data for breast cancer drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Illumina to lay off 10% of research and development team

entertainment

The strange history of BMI, the body mass index

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Medical experts exlpore how to eliminate bias in clinical algorithms

ASCO: Palliative care found as helpful given virtually as in person

Here's how to stay safe from wildfire smoke amid reduced air quality

With trial win, GSK could get blood cancer drug back on market

knowledge

focus

focus

hotspot